These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22673007)

  • 1. Treatment of overactive bladder with botulinum toxin: are there more challenges to deal with?
    Apostolidis A
    Eur Urol; 2012 Sep; 62(3):515-7. PubMed ID: 22673007
    [No Abstract]   [Full Text] [Related]  

  • 2. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions.
    Madersbacher S
    Eur Urol; 2013 Aug; 64(2):257-9. PubMed ID: 23731721
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply from author re: Stephan Madersbacher. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions. Eur Urol 2013;64:257-9: OnabotulinumtoxinA for idiopathic overactive bladder symptoms: some answers but even more questions.
    Chapple CR
    Eur Urol; 2013 Nov; 64(5):e100-1. PubMed ID: 23830474
    [No Abstract]   [Full Text] [Related]  

  • 4. Tips and Tricks in Intra-Detrusor Botulinum Toxin A (BoNTA) Injections.
    Corcos J; Biardeau X; Aharony S
    World J Urol; 2015 Jun; 33(6):899-901. PubMed ID: 26217823
    [No Abstract]   [Full Text] [Related]  

  • 5. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease.
    Kulaksizoglu H; Parman Y
    Parkinsonism Relat Disord; 2010 Sep; 16(8):531-4. PubMed ID: 20637678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
    Ellsworth P; Travis M
    Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new treatment for overactive bladder.
    Mayo Clin Health Lett; 2013 Jul; 31(7):4. PubMed ID: 24712053
    [No Abstract]   [Full Text] [Related]  

  • 9. [INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
    Krivoborodov GG; Tur EI; Efremov NS
    Urologiia; 2015; (2):31-4. PubMed ID: 26237802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
    Nambiar A; Lucas M
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
    Wein AJ
    J Urol; 2014 May; 191(5):1340-1. PubMed ID: 24745503
    [No Abstract]   [Full Text] [Related]  

  • 12. Submucosal injections of botulinum toxin A in women with refractory idiopathic detrusor overactivity.
    Onyeka BA; Shetty A; Ilangovan K; Saxena A
    Int J Gynaecol Obstet; 2010 Jul; 110(1):68-9. PubMed ID: 20347085
    [No Abstract]   [Full Text] [Related]  

  • 13. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targets for botulinum toxin in the lower urinary tract.
    Cruz F
    Neurourol Urodyn; 2014 Jan; 33(1):31-8. PubMed ID: 23775898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder.
    Chapple C
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S1. PubMed ID: 25042136
    [No Abstract]   [Full Text] [Related]  

  • 16. Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. Onabotulinumtoxina.
    Doggweiler R
    J Urol; 2011 Jun; 185(6):2023-4. PubMed ID: 21496846
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Harris MA; Harding C; Fulford S; Whiteway J
    BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980
    [No Abstract]   [Full Text] [Related]  

  • 18. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins.
    Apostolidis A
    Expert Opin Pharmacother; 2011 May; 12(7):1029-39. PubMed ID: 21288184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.